Behavioural genetics of Alzheimer's disease: A comprehensive review

Archives of Medical Science

Volumn 7, Issue 2, 2011, Pages 195-210

  Flirski, Marcin ^a   Sobow, Tomasz ^a   Kloszewska, Iwona ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Alzheimer's disease; Behavioural and psychological symptoms of dementia; Behavioural disturbances; Genetics; Polymorphisms

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; APOLIPOPROTEIN E; CATECHOL METHYLTRANSFERASE; DOPAMINE RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; TRYPTOPHAN HYDROXYLASE;

ALZHEIMER DISEASE; BEHAVIOR GENETICS; BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA; DEMENTIA; HUMAN; NEUROTRANSMISSION; PHYSICAL DISEASE BY BODY FUNCTION; REVIEW; RISK; SYSTEMATIC REVIEW;

EID: 79956349501     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2011.22068     Document Type: Review

References (113)

1. Hart DJ, Craig D, Compton SA, et al. A retrospective study of the behavioural and psychological symptoms of mid and late phase Alzheimer's disease. Int J Geriatr Psychiatry 2003; 18: 1037-42. (Pubitemid 37479377)
2. Lopez OL, Wisniewski SR, Becker JT, Boller F, DeKosky ST. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol 1999; 56: 1266-72. (Pubitemid 29473220)
3. Moritz DJ, Fox PJ, Luscombe FA, Kraemer HC. Neurological and psychiatric predictors of mortality in patients with Alzheimer disease in California. Arch Neurol 1997; 54: 878-85. (Pubitemid 27306625)
4. Ferris SH, Steinberg G, Shulman E, Kahn R, Reisberg B. Institutionalization of Alzheimer's disease patients: reducing precipitating factors through family counseling. Home Health Care Serv Q 1987; 8: 23-51.
5. Clyburn LD, Stones MJ, Hadjistavropoulos T, Tuokko H. Predicting caregiver burden and depression in Alzheimer's disease. J Gerontol B Psychol Sci Soc Sci 2000; 55: S2-13.
6. Cohen-Mansfield J, Mintzer JE. Time for change: the role of nonpharmacological interventions in treating behavior problems in nursing home residents with dementia. Alzheimer Dis Assoc Disord 2005; 19: 37-40. (Pubitemid 40940997)
7. Lanctôt KL, Herrmann N, Mazzotta P. Role of serotonin in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci 2001; 13: 5-21. (Pubitemid 32151912)
8. Sweet RA, Nimgaonkar VL, Kamboh MI, Lopez OL, Zhang F, DeKosky ST. Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease. Arch Neurol 1998; 55: 1335-40. (Pubitemid 28465867)
9. Herrmann N, Lanctôt KL, Khan LR. The role of norepinephrine in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci 2004; 16: 261-76. (Pubitemid 39244552)
10. Minger SL, Esiri MM, McDonald B, et al. Cholinergic deficits contribute to behavioral disturbance in patients with dementia. Neurology 2000; 55: 1460-7.
11. Lanctôt KL, Herrmann N, Mazzotta P, Khan LR, Ingber N. GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Can J Psychiatry 2004; 49: 439-53. (Pubitemid 39071365)
12. Herrmann N, Lanctôt KL. Pharmacologic management of neuropsychiatric symptoms of Alzheimer's disease. Can J Psychiatry 2007; 52: 630-46. (Pubitemid 350085594)
13. Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL. Neuropathologic correlates of apathy in Alzheimer's disease. Dement Geriatr Cogn Disord 2006; 21: 144-7. (Pubitemid 43201323)
14. Lee DY, Choo IH, Kim KW, et al. White matter changes associated with psychotic symptoms in Alzheimer's disease patients. J Neuropsychiatry Clin Neurosci 2006; 18: 191-8.
15. Edwards-Lee T, Cook I, Fairbanks L, Leuchter A, Cummings JL. Quantitative electroencephalographic correlates of psychosis in Alzheimer disease. Neuropsychiatry Neuropsychol Behav Neurol 2000; 13: 163-70. (Pubitemid 30495476)
16. Tanzi RE. A genetic dichotomy model for the inheritance of Alzheimer's disease and common age-related disorders. J Clin Invest 1999; 104: 1175-9. (Pubitemid 29536288)
17. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-3.
18. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009; 63: 287-303.
19. Lehtovirta M, Soininen H, Helisalmi S, et al. Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: Relation to apolipoprotein E polymorphism. Neurology 1996; 46: 413-9. (Pubitemid 26081323)
20. Ramachandran G, Marder K, Tang M, et al. A preliminary study of apolipoprotein E genotype and psychiatric manifestations of Alzheimer's disease. Neurology 1996; 47: 256-9. (Pubitemid 26243894)
21. Holmes C, Levy R, McLoughlin DM, Powell JF, Lovestone S. Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry 1996; 61: 580-3. (Pubitemid 27023334)
22. Holmes C, McLoughlin DM, Powell J, Lovestone S. Reply. J Neurol Neurosurg Psychiatry 1997; 63: 273-4.
23. Holmes C, Russ C, Kirov G, et al. Apolipoprotein E: depressive illness, depressive symptoms and Alzheimer's disease. Biol Psychiatry 1998; 43: 159-64. (Pubitemid 28096552)
24. Ballard C, Massey H, Lamb H, Morris C. Apolipoprotein E: non-cognitive symptoms and cognitive decline in late-onset Alzheimer's disease. J Neurol Neurosurg Psychiatr 1997; 63: 273-4.
25. Cacabelos R, Rodriguez B, Carrera C, Beyer K, Lao JI, Sellers MA. Behavioral changes associated with different apolipoprotein E genotypes in dementia. Alzheimer Dis Assoc Disord 1997; 11: S27-34.
26. Cantillon M, Harwood D, Barker W, et al. No association between apolipoprotein E genotype and late-onset depression in Alzheimer's disease. Biol Psychiatry 1997; 41: 246-8. (Pubitemid 27062670)
27. Forsell Y, Corder EH, Basun H, Lannfelt L, Viitanen M, Winblad B. Depression and dementia in relation to apolipoprotein E polymorphism in a population sample age 75+. Biol Psychiatry 1997; 42: 898-903. (Pubitemid 27486443)
28. Forsell Y, Basun H, Corder EH, Lannfelt L, Winblad B. Psychotic symptoms and apolipoprotein E genotypes in an elderly population. Biol Psychiatry 1998; 44: 139-40. (Pubitemid 28305533)
29. Lopez OL, Kamboh MI, Becker JT, Kaufer DI, DeKosky ST. The apolipoprotein E e4 allele is not associated with psychiatric symptoms or extrapyramidal signs in probable Alzheimer's disease. Neurology 1997; 49: 794-7. (Pubitemid 27428024)
30. Lyketsos CG, Baker L, Warren A, et al. Depression, delusions and hallucinations in Alzheimer's Disease: No relationship to apolipoprotein E genotype. J Neuropsychiatr Clin Neurosci 1997; 9: 64-7. (Pubitemid 27075415)
31. Murphy GM Jr, Taylor J, Tinklenberg JR, Yesavage JA. The apolipoprotein E epsilon 4 allele is associated with increased behavioral disturbance in Alzheimer's disease. Am J Geriatr Psychiatry 1997; 5: 88-9. (Pubitemid 27021088)
32. Hirono N, Mori E, Yasuda M, et al. Factors associated with psychotic symptoms in Alzheimer's disease. J Neurol Neurosurg Psychiatr 1998; 648-52. (Pubitemid 28204153)
33. Hirono N, Mori E, Yasuda M, et al. Lack of effect of apolipoprotein E E4 allele on neuropsychiatric manifestations in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1999; 11: 66-70. (Pubitemid 29070666)
34. Harwood DG, Barker WW, Ownby RL, St. George-Hyslop PH, Duara R. Apolipoprotein-E (APO-E) genotype and symptoms of psychosis in Alzheimer's disease. Am J Geriatr Psychiatr 1999; 7: 119-23. (Pubitemid 29165460)
35. Levy ML, Cummings JL, Fairbanks LA, Sultzer DL, Small GW. Apolipoprotein E genotype and noncognitive symptoms in Alzheimer's disease. Biol Psychiatr 1999; 45: 422-5. (Pubitemid 29130439)
36. Weiner MF, Vega G, Risser RC, et al. Apolipoprotein E epsilon 4, other risk factors, and course of Alzheimer's disease. Biol Psychiatry 1999; 45: 633-8. (Pubitemid 29147373)
37. Gabryelewicz T, Religa D, Styczynska M, et al. Behavioural pathology in Alzheimer's disease with special reference to apolipoprotein E genotype. Dement Geriatr Cogn Disord 2002; 14: 208-12. (Pubitemid 36151488)
38. Scarmeas N, Brandt J, Albert M, et al. Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease. Neurology 2002; 58: 1182-8. (Pubitemid 34411861)
39. Sweet R, Kamboh MI, Wisniewski SR, et al. Apolipoprotein E and alpha-1-antichymotrypsin genotypes do not predict time to psychosis in Alzheimer's disease. J Geriatr Psychiatr Neurol 2002; 15: 24-30. (Pubitemid 34219882)
40. Chang JB, Wang PN, Chen WT, et al. ApoE epsilon4 allele is associated with incidental hallucinations and delusions in patients with AD. Neurology 2004; 63: 1105-7. (Pubitemid 39287928)
41. Craig D, Hart D, McCool K, McIlroy S, Passmore A. Apolipoprotein E e4 allele influences aggressive behaviour in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004; 75: 1327-30. (Pubitemid 39141343)
42. Craig D, Hart DJ, McIlroy SP, Passmore AP. Association analysis of apolipoprotein E genotype and risk of depressive symptoms in Alzheimer's disease. Dement Geriatr Cogn Disord 2005; 19: 154-7. (Pubitemid 40868043)
43. Robertson J, Curley J, Kaye J, Quinn J, Pfankuch T, Raber J. APOE isoforms and measures of anxiety in probable AD patients and apoe -/- mice. Neurobiol Aging 2005; 26: 637-43. (Pubitemid 40228755)
44. Borroni B, Grassi M, Agosti C, et al. Cumulative effect of COMT and 5-HTTLPR polymorphisms and their interaction with disease severity and comorbidities on the risk of psychosis in Alzheimer disease. Am J Geriatr Psychiatry 2006; 14: 343-51.
45. Borroni B, Grassi M, Agosti C, et al. Genetic correlates of behavioral endophenotypes in Alzheimer disease: role of COMT, 5-HTTLPR and APOE polymorphisms. Neurobiol Aging 2006; 27: 1595-603. (Pubitemid 44363107)
46. Craig D, Hart DJ, Passmore AP. Genetically increased risk of sleep disruption in Alzheimer's disease. Sleep 2006; 29: 1003-7. (Pubitemid 44257376)
47. Engelborghs S, Dermaut B, Mariën P, et al. Dose dependent effect of APOE epsilon4 on behavioral symptoms in frontal lobe dementia. Neurobiol Aging 2006; 27: 285-92. (Pubitemid 43038553)
48. Spalletta G, Bernardini S, Bellincampi L, Federici G, Trequattrini A, Caltagirone C. Delusion symptoms are associated with ApoE epsilon4 allelic variant at the early stage of Alzheimer's disease with late onset. Eur J Neurol 2006; 13: 176-82.
49. Pritchard AL, Harris J, Pritchard CW, et al. The effect of the apolipoprotein E gene polymorphisms and haplotypes on behavioural and psychological symptoms in probable Alzheimer's disease. J Neurol Neurosurg Psychiatry 2007; 78: 123-6. (Pubitemid 46220206)
50. Sobow T, Kloszewska I, Flirski M, Golanska E, Liberski PP. Apoliprotein E genotype and its relation to behavioral and psychological symptoms in Alzheimer's disease [Polish]. Post Psych Neurol 2007; 16: 215-220.
51. Zdanys KF, Kleiman TG, MacAvoy MG, et al. Apolipoprotein E epsilon4 allele increases risk for psychotic symptoms in Alzheimer's disease. Neuropsychopharmacology 2007; 32: 171-9. (Pubitemid 44967795)
52. Borroni B, Archetti S, Costanzi C, et al.; ITINAD Working Group. Role of BDNF Val66Met functional polymorphism in Alzheimer's disease-related depression. Neurobiol Aging 2009; 30: 1406-12.
53. Grünblatt E, Zehetmayer S, Bartl J, et al. Genetic risk factors and markers for Alzheimer's disease and/or depression in the VITA study. J Psychiatr Res 2009; 43: 298-308.
54. Quaranta D, Bizzarro A, Marra C, et al. Psychotic symptoms in Alzheimer's disease and 5-HTTLPR polymorphism of the serotonin transporter gene: evidence for an association. J Alzheimers Dis 2009; 16: 173-80.
55. Woods DL, Bushnell B, Kim H, Geschwind D, Cummings J. Apolipoprotein epsilon4 status is associated with behavioral symptoms in nursing home residents with dementia. Int Psychogeriatr 2009; 21: 722-8.
56. Tekin S, Mega MS, Masterman DM, et al. Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann Neurol 2001; 49: 355-61. (Pubitemid 32202789)
57. Cherbuin N, Leach LS, Christensen H, Anstey KJ. Neuroimaging and APOE genotype: a systematic qualitative review. Dement Geriatr Cogn Disord 2007; 24: 348-62. (Pubitemid 350036691)
58. Rosen HJ, Allison SC, Schauer GF, Gorno-Tempini ML, Weiner MW, Miller BL. Neuroanatomical correlates of behavioural disorders in dementia. Brain 2005; 128: 2612-25. (Pubitemid 41552946)
59. Lanctôt KL, Herrmann N, Nadkarni NK, Leibovitch FS, Caldwell CB, Black SE. Medial temporal hypoperfusion and aggression in Alzheimer disease. Arch Neurol 2004; 61: 1731-7. (Pubitemid 39463431)
60. Barnes N, Sharp T. A review of central 5HT receptors and their functions. Neuropharmacology 1999; 38: 1083-152. (Pubitemid 29292403)
61. Norton N, Owen M. HTR2A: association and expression studies in neuropsychiatric genetics. Ann Med 2005; 37: 121-9.
62. Holmes C, Arranz M, Powell J, Collier D, Lovestone S. 5HT2A and 5HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease. Hum Mol Genet 1998; 7: 1507-9. (Pubitemid 28429933)
63. Nacmias B, Tedde A, Forleo P, et al. Association between 5HT2A receptor polymorphism and psychotic symptoms in Alzheimer's disease. Biol Psychiatry 2001; 50: 472-5. (Pubitemid 32885599)
64. Holmes C, Arranz M, Collier D, Powell J, Lovestone S. Depression in Alzheimer's disease: the effect of serotonin receptor gene variation. Am J Med Genet (Neuropsychiatric Genet) 2003; 119B: 40-3. (Pubitemid 37064051)
65. Rocchi A, Micheli R, Ceravolvo M, et al. Serotonergic polymorphisms (5-HTTLPR and 5-HT2A): association studies with psychosis in Alzheimer's disease. Genet Test 2003; 7: 309-14. (Pubitemid 38199264)
66. Assal F, Alarcon M, Soloman E, Masterman D, Geshwind D, Cummings J. Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer's disease. Arch Neurol 2004; 61: 1249-53.
67. Wa Lam L, Tang N, Ma S, Zhang W, Chiu K. 5-HT2A T102C receptor polymorphism and neuropsychiatric symptoms in Alzheimer's disease. Int J Geriatric Psychiatry 2004; 19: 523-6. (Pubitemid 38877999)
68. Micheli D, Bonvicini C, Rocchi A, et al. No evidence for allelic association of serotonin 2A receptor and transporter gene polymorphisms with depression in Alzheimer disease. J Alzheimers Dis 2006; 10: 371-8.
69. Craig D, Donnelly C, Hart D, Carson R, Passmore P. Analysis of the 5HT-2A T102C receptor polymorphism and psychotic symptoms in Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 126-8. (Pubitemid 46122650)
70. Wilkosz PA, Kodavali C, Weamer EA, et al. Prediction of psychosis onset in Alzheimer disease: the role of depression symptom severity and the HTR2A T102C polymorphism. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 1054-62. (Pubitemid 350207781)
71. Pritchard AL, Harris J, Pritchard CW, et al. Role of 5HT 2A and 5HT 2C polymorphisms in behavioural and psychological symptoms of Alzheimer's disease. Neurobiol Aging 2008; 29: 341-7. (Pubitemid 351215579)
72. Angelucci F, Bernardini S, Gravina P, et al. Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102T/C) in Alzheimer's disease: a 3-year follow-up longitudinal study. J Alzheimers Dis 2009; 17: 203-11.
73. Liu HC, Hong CJ, Liu CY, et al. Association analysis of the 5-HT6 receptor polymorphism C267T with depression in patients with Alzheimer's disease. Psychiatry Clin Neurosci 2001; 55: 427-9.
74. Polesskaya OO, Sokolov BP. Differential expression of the "C" and "T" alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res 2002; 67: 812-22.
75. Serretti A, Drago A, De Ronchi D. HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Curr Med Chem 2007; 14: 2053-69. (Pubitemid 47578163)
76. Drago A, Serretti A. Focus on HTR2C: a possible suggestion for genetic studies of complex disorders. Am J Med Genet Part B 2009; 150B: 601-37.
77. Berg KA, Clarke WP, Cunningham KA, Spampinato U. Fine-tuning serotonin2c receptor function in the brain: molecular and functional implications. Neuropharmacology 2008; 55: 969-76.
78. Haddley K, Vasiliou AS, Ali FR, Paredes UM, Bubb VJ, Quinn JP. Molecular genetics of monoamine transporters: relevance to brain disorders. Neurochem Res 2008; 33: 652-67. (Pubitemid 351341639)
79. Li T, Holmes C, Sham PC, et al. Allelic functional variation of serotonin transporter expression is a susceptibility factor for late onset Alzheimer's disease. Neuroreport 1997; 8: 683-6. (Pubitemid 27128217)
80. Sukonick DL, Pollock BG, Sweet RA, et al. The 5-HTTPR*S/*L polymorphism and aggressive behavior in Alzheimer disease. Arch Neurol 2001; 58: 1425-8. (Pubitemid 32845994)
81. Sweet RA, Pollock BG, Sukonick DL, et al. The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimer disease. Int Psychogeriatr 2001; 13: 401-9. (Pubitemid 34326969)
82. Ha TM, Cho DM, Park SW, et al. Evaluating associations between 5-HTTLPR polymorphism and Alzheimer's disease for Korean patients. Dement Geriatr Cogn Disord 2005; 20: 31-4.
83. Pritchard AL, Pritchard CW, Bentham P, Lendon CL. Role of serotonin transporter polymorphisms in the behavioural and psychological symptoms in probable Alzheimer disease patients. Dement Geriatr Cogn Disord 2007; 24: 201-6. (Pubitemid 47312670)
84. Ueki A, Ueno H, Sato N, Shinjo H, Morita Y. Serotonin transporter gene polymorphism and BPSD in mild Alzheimer's disease. J Alzheimers Dis 2007; 12: 245-53. (Pubitemid 350179257)
85. Albani D, Prato F, Tettamanti M, et al. The serotonin transporter promoter polymorphic region is not a risk factor for Alzheimer's disease related behavioral disturbances. J Alzheimers Dis 2009; 18: 125-30.
86. Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002; 159: 460-5. (Pubitemid 34184743)
87. Munafò MR, Brown SM, Hariri AR. Serotonin transporter (5-HTTLPR) genotype and amygdala activation: a meta-analysis. Biol Psychiatry 2008; 63: 852-7. (Pubitemid 351458448)
88. D'Souza UM, Craig IW. Functional genetic polymorphisms in serotonin and dopamine gene systems and their significance in behavioural disorders. Prog Brain Res 2008; 172: 73-98.
89. Hu XZ, Lipsky RH, Zhu G, et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 2006; 78: 815-26.
90. Luddington NS, Mandadapu A, Husk M, El-Mallakh RS. Clinical implications of genetic variation in the serotonin transporter promoter region: a review. Prim Care Companion J Clin Psychiatry 2009; 11: 93-102.
91. Parsey RV, Hastings RS, Oquendo MA, et al. Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain. Am J Psychiatry 2006; 163: 48-51. (Pubitemid 43050102)
92. Akil M, Kolachana BS, Rothmond DA, Hyde TM, Weinberger DR, Kleinman JA. Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J Neurosci 2003; 23: 2008-13. (Pubitemid 36368887)
93. Glatt S, Faraone SV, Tsuang MT. Association between a functional catechol-O-methyltransferasegene polymorphism and schizoprenia: meta-analysis of case-control and family-based studies. Am J Psychiatry 2003; 160: 469-76. (Pubitemid 41094254)
94. Tan HY, Callicott JH, Weinberger DR. Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. Cereb Cortex 2007; Suppl 1: i171-81.
95. Borroni B, Agosti C, Archetti S, et al. Catechol-O-methyltransferase gene polymorphism is associated with risk of psychosis in Alzheimer Disease. Neurosci Lett 2004; 370: 127-9. (Pubitemid 39370865)
96. Sweet RA, Devlin B, Pollock BG, et al. Catechol-O-methyltransferase haplotypes are associated with psychosis in Alzheimer disease. Mol Psychiatry 2005; 10: 1026-36. (Pubitemid 41541988)
97. Borroni B, Grassi M, Costanzi C, et al. Haplotypes in cathechol-O-methyltransferase gene confer increased risk for psychosis in Alzheimer disease. Neurobiol Aging 2007; 28: 1231-8. (Pubitemid 46824011)
98. Barnett JH, Scoriels L, Munafò MR. Meta-analysis of the cognitive effects of the catechol-O-methyltransferase gene Val158/108Met polymorphism. Biol Psychiatry 2008; 64: 137-44.
99. Jönsson EG, Kaiser R, Brockmöller J, Nimgaonkar VL, Crocq MA. Meta-analysis of the dopamine D3 receptor gene (DRD3) Ser9Gly variant and schizophrenia. Psychiatr Genet 2004; 14: 9-12. (Pubitemid 38393526)
100. Reeves S, Brown R, Howard R, Grasby P. Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer disease. Neurology 2009; 72: 528-34.
101. Holmes C, Smith H, Ganderton R, et al. Psychosis and aggression in Alzheimer's disease: the effect of dopamine receptor gene variation. J Neurol Neurosurg Psychiatry 2001; 71: 777-9. (Pubitemid 33121920)
102. Craig D, Hart DJ, Carson R, McIlroy SP, Passmore AP. Psychotic symptoms in Alzheimer's disease are not influenced by polymorphic variation at the dopamine receptor DRD3 gene. Neurosci Lett 2004; 368: 33-6. (Pubitemid 39178743)
103. Pritchard AL, Ratcliffe L, Sorour E, et al. Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer's disease. Int J Geriatr Psychiatry 2009; 24: 1020-5.
104. Sato N, Ueki A, Ueno H, Shinjo H, Morita Y. Dopamine D3 receptor gene polymorphism influences on behavioral and psychological symptoms of dementia (BPSD) in mild dementia of Alzheimer's type. J Alzheimers Dis 2009; 17: 441-8.
105. Pritchard AL, Pritchard CW, Bentham P, Lendon CL. Investigation of the role of the dopamine transporter in susceptibility to behavioural and psychological symptoms of patients with probable Alzheimer's disease. Dement Geriatr Cogn Disord 2008; 26: 257-60.
106. Craig D, Hart DJ, McCool K, McIlroy SP, Passmore AP. The interleukin 1beta gene promoter polymorphism (-511) acts as a risk factor for psychosis in Alzheimer's dementia. Ann Neurol 2004; 56: 121-4. (Pubitemid 38857367)
107. McCulley MC, Day IN, Holmes C. Association between interleukin 1-beta promoter (-511) polymorphism and depressive symptoms in Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2004; 124B: 50-3. (Pubitemid 38031592)
108. Clarimón J, Bertranpetit J, Boada M, Tàrraga L, Comas D. HSP70-2 (HSPA1B) is associated with noncognitive symptoms in late-onset Alzheimer's disease. J Geriatr Psychiatry Neurol 2003; 16: 146-50. (Pubitemid 37409023)
109. Spalletta G, Bernardini S, Bellincampi L, et al. Glutathione S-transferase P1 and T1 gene polymorphisms predict longitudinal course and age at onset of Alzheimer disease. Am J Geriatr Psychiatry 2007; 15: 879-87.
110. Craig D, Hart DJ, Carson R, McIlroy SP, Passmore AP. Allelic variation at the A218C tryptophan hydroxylase polymorphism influences agitation and aggression in Alzheimer's disease. Neurosci Lett 2004; 363: 199-202. (Pubitemid 38746512)
111. Go RC, Perry RT, Wiener H, et al. Neuregulin-1 polymorphism in late onset Alzheimer's disease families with psychoses. Am J Med Genet B Neuropsychiatr Genet 2005; 139B: 28-32. (Pubitemid 41552293)
112. Sato N, Ueki A, Ueno H, Shinjo H, Morita Y. IDE Gene Polymorphism influences on BPSD in mild dementia of Alzheimer's type. Curr Gerontol Geriatr Res 2008; 858759.
113. Sato S, Mizukami K, Asada T. A preliminary open-label study of 5-HT1A partial agonist tandospirone for behavioural and psychological symptoms associated with dementia. Int J Neuropsychopharm 2007; 10: 281-3.